Valuation: Poltreg S.A.

Market Cap 121M 30.89M 27.56M 25.67M 23.36M 44M 2.97B 44.32M 310M 1.52B 116M 113M 4.88B P/E 2024
-9.12x
P/E 2025 -4.39x
Enterprise Value 111M 28.29M 25.24M 23.51M 21.4M 40.29M 2.72B 40.59M 284M 1.39B 106M 104M 4.47B EV / Sales 2024
380x
EV / Sales 2025 -
Free-Float
67.57%
Yield 2024 *
-
Yield 2025 -
1 day+0.49%
1 week-5.99%
Current month-0.49%
1 month-6.85%
3 months+10.87%
6 months+16.24%
Current year-16.73%
1 week 19.2
Extreme 19.2
21.2
1 month 19.1
Extreme 19.1
23.4
Current year 16
Extreme 16
28.6
1 year 16
Extreme 16
29.8
3 years 16
Extreme 16
60
5 years 16
Extreme 16
73.9
10 years 16
Extreme 16
73.9
Manager TitleAgeSince
Chief Executive Officer - 01/05/2019
Chief Tech/Sci/R&D Officer - 01/11/2021
Corporate Officer/Principal - 21/02/2024
Director TitleAgeSince
Chairman - 24/05/2021
Director/Board Member 51 21/05/2021
Director/Board Member 43 01/06/2023
Change 5-day change 1-year change 3-year change Capi.($)
+0.49%-5.99%-17.07%-65.42% 30.88M
+4.16%+3.42%+49.37%+94.17% 74.16B
-0.37%-3.81%+19.75%+78.12% 57.39B
+1.63%-1.61%+3.83%+36.89% 47.64B
+0.50%+2.94%+344.62%+722.17% 44.29B
+3.05%-1.80%+28.78%+34.51% 42.5B
+1.00%-1.46%+5.17%+111.90% 40.71B
-0.54%+2.41%+9.31%+58.85% 30.97B
+4.33%+8.04%+37.62%+32.27% 28.53B
+0.76%-1.45%-7.44%-11.12% 24.34B
Average +1.50%-0.12%+47.39%+109.23% 39.06B
Weighted average by Cap. +1.75%-0.41%+58.51%+137.50%

Financials

2024 2025
Net sales 350K 89.58K 79.91K 74.45K 67.75K 128K 8.63M 129K 900K 4.4M 336K 329K 14.15M -
Net income -18.71M -4.79M -4.27M -3.98M -3.62M -6.82M -461M -6.87M -48.08M -235M -17.97M -17.59M -757M -26M -6.65M -5.94M -5.53M -5.03M -9.48M -641M -9.55M -66.82M -327M -24.98M -24.44M -1.05B
Net Debt -37.69M -9.65M -8.6M -8.02M -7.3M -13.74M -929M -13.84M -96.86M -474M -36.21M -35.43M -1.52B -10.16M -2.6M -2.32M -2.16M -1.97M -3.7M -251M -3.73M -26.12M -128M -9.76M -9.55M -411M
Logo Poltreg S.A.
Poltreg SA is a Poland-based company engaged primarily in biotechnology and medical research. The Company conducts research in the field of autoimmunological diseases. The Company works on a method of healing, that uses t-regulated cells (TREGs). The Firm possesses its own, patented technology to obtain T-regulated lymphocytes, that are used in the therapy. The Company works on therapy for diseases such as type one diabetes, type two diabetes, and multiple sclerosis. In its research, the Company cooperates with multiple specialists from various fields of science. The Company is developing its own research center, which is intended as a basic location for conducting future research activities.
Employees
34
Date Price Change Volume
05/10/26 PLN 20.40 +0.49% 2,474
02/10/26 PLN 20.30 -0.49% 1,287
01/10/26 PLN 20.40 -0.49% 4,187
30/09/26 PLN 20.50 -1.91% 10,393
29/09/26 PLN 20.90 -3.69% 8,180

Quarterly revenue - Rate of surprise